Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Don't miss these five impressive spots in Bangkok - 2EU top diplomat Kallas arrives in Kiev to commemorate Bucha massacre
- 3Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
- 4NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
- 5Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- Damaged Shenzhou-20 spacecraft to return to Earth uncrewed for inspection
- Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- Activists guilty over Palestine protest breach
- France bans Muslim gathering citing risk to participants
- Vote In favor of Your Favored Keeping an eye on
- Pick Your Favored method of transportation
- Antivirus Programming for Exhaustive Security
- Russian strikes on Ukraine kill 5 people and wound 30 more
